Eastern Idaho - Geographic Area Reports - Statistical Data

COMPARISON OF CANCER INCIDENCE RATES
BETWEEN SELECTED COUNTIES AND THE REMAINDER OF THE STATE OF IDAHO

CANCER DATA REGISTRY OF IDAHO
IDAHO HOSPITAL ASSOCIATION

AND

CANCER CLUSTER ANALYSIS WORK GROUP
DIVISION OF HEALTH
IDAHO DEPARTMENT OF HEALTH AND WELFARE

Stacey Peterson, A.R.T, C.T.R., Director
Cancer Data Registry of Idaho

Christopher J. Johnson, MPH
Supervisor, Surveillance and Planning
Center for Vital Statistics and Health Policy

March 1995


COMPARISON OF CANCER INCIDENCE RATES
BETWEEN SELECTED COUNTIES AND THE REMAINDER OF THE STATE OF IDAHO

HISTORY

In February, 1995, Stacey Peterson, Director, Cancer Data Registry of Idaho (CDRI) was contacted by Colleen LaMay, Idaho Statesman, regarding an investigation of cancer incidence in 17 selected counties. The counties of interest to Ms. LaMay and which, therefore, comprised the study area were: Bannock, Bingham, Blaine, Bonneville, Butte, Caribou, Cassia, Clark, Custer, Fremont, Jefferson, Jerome, Lincoln, Madison, Minidoka, Power, and Twin Falls. The remaining 27 counties in Idaho comprised the area from which comparison cancer incidence rates were calculated. Ms. LaMay was referred to Christopher Johnson, Center for Vital Statistics and Health Policy, Division of Health, who provided a listing of sites and types of cancer with established relationships to ionizing radiation sources (from Biological Effects of Ionizing Radiations V, 1990). Although the timeframe of interest for this study was since 1969, the beginning of CDRI data collection, it was limited to 1971 to 1992, the period for which CDRI possesses a complete, population-based registry of cancer cases in Idaho.

Because the Rocky Mountain Cancer Data System software utilized by CDRI is set up to utilize the state of Idaho as a comparison area for studies of cancer incidence, and not groupings of counties such as comprise the 27 county comparison area, analysis was requested from and provided by the Center for Vital Statistics and Health Policy. Prior to the completion of this report, the methodology and results were reviewed by CDRI staff and the Cancer Cluster Analysis Work Group (Supervisor and Toxicologist, Office of Environmental Health; Supervisor and Health Policy Analyst, Health Statistics Section, Center for Vital Statistics and Health Policy; State Epidemiologist, Bureau of Communicable Disease Prevention; Director, Cancer Data Registry of Idaho).

METHODS

Using data from the Cancer Data Registry of Idaho (CDRI), the Centers for Disease Control and Prevention (CDC), the Bureau of the Census, and the Center for Vital Statistics and Health Policy, cancer incidence for the 17 counties in the study area was compared to the remainder of the state for the years 1971 to 1992. The cancer sites and types for which incidence comparisons were made were: (1) parotid/salivary, (2) esophagus, (3) stomach, (4) colon, (5) rectosigmoid/rectum, (6) liver, (7) sinus/paranasal, (8) lung/bronchus, (9) bone, (10) female breast, (11) ovary, (12) bladder, (13) kidney/renal pelvis, (14) brain/central nervous system (CNS), (15) thyroid, (16) parathyroid, (17) non-Hodgkin's lymphoma, (18) multiple myeloma, and (19) leukemia. Because of the small number of cases statewide for cancer of the parathyroid, comparisons were not conducted for this site. Cancer cases were abstracted by the CDRI for Idaho residents only. The data elements used were primary cancer site code, histology code, age at diagnosis, sex, and county of residence at diagnosis. Person-years (a measure of the length of time a person is at risk for disease), the denominators for incidence rates, were calculated by adding 1991 and 1992 Center for Vital Statistics and Health Policy population estimates by age, sex, and county to 1971-1990 person-year estimates from the CDC.

Standardized morbidity ratios were calculated using the indirect method. Comparison incidence rates for each site and type of cancer by age and sex were calculated by aggregating cases and person-years for the 27 counties in the comparison area. These rates were multiplied by age and sex specific person-year estimates for each of the counties in the study area to determine the expected number of cases for each site and type of cancer in each study county. Probabilities of the observed numbers of cases exceeding those expected were calculated based upon the Poisson probability distribution, using a one-tailed test. For those cases where expected exceeded observed, no p-values were calculated. All statistical tests were performed using SAS software.

RESULTS AND DISCUSSION

The tables on pages 4 to 13 list the number of observed cases, expected cases, the standardized morbidity ratio, and the unadjusted p-value for each cancer site/type by county. A total of 324 observed to expected comparisons were performed. Based upon chance alone, it was expected that 16 of the 324 comparisons would have shown statistically significant elevations at p=.05. Fourteen statistically significant elevations were found. While adjustment for multiple tests is warranted, the p-values shown do not adjust for the number of tests performed. Using the Bonferroni (Jones and Rushton, 1982) or Tippett's (1952) adjustment, none of the cancer sites or types were significantly elevated at the .05 level in any of the 17 counties studied or the conglomerate study area.

The table on page 14 shows cancer incidence rates for Idaho, 1983 to 1992, as compared with Surveillance and Epidemiology End Results (SEER) rates for 1987 to 1991. SEER is a program of the National Cancer Institute that collects cancer data from 9 states representing 13.9% of the United States population. The states were chosen such that SEER rates are representative of the nation. This provides a frame of reference for interpreting the cancer incidence in Idaho and counties within Idaho. Some of the site/type categories listed on page 14 differ from those presented in the previous tables on pages 4 to 13 due to the availability and comparability of SEER data. Overall, cancer incidence in Idaho is significantly lower than SEER rates.

Several behavioral risks and other factors related to cancer were not addressed in this ecologic study. While all of the cancer sites/types selected for inclusion in this study are sensitive to ionizing radiation (BEIR V: ionizing radiation has been associated with an increase in cancer incidence), the cancer sites/types are not specific to radiation. (Other agents have been linked to increases in incidence, such as smoking tobacco and lung cancer.) Although some studies of irradiated cohorts have provided dose-incidence data for skin cancer, such studies have been complicated by the fact that skin cancer carries a low mortality and is grossly underreported (BEIR V). The Cancer Data Registry of Idaho collects data on basal and squamous cell carcinoma only for mucous membranes. For these reasons, skin cancer was not included in this study. Migration patterns were not taken into account. Persons may have resided in counties other than those in the study area or outside of the state of Idaho for most of their lives, but have been diagnosed with cancer after moving to one of these areas. In such circumstances, conditions in these areas would be unrelated to cancer etiology. Other risk factors not investigated in the study include diet, drinking, smoking habits, and familial history, all of which have been linked with several cancer sites/types.

A fundamental limitation of ecologic studies such as this is the inability to link cancer rates to causes. Because no person-specific exposure data are available, there is no evidence to conclude that elevated environmental contaminants or other etiologic sources caused cancer. Consequently, cause and effect relationships are not discernable for any excess cancer incidence identified by ecologic studies.


Bannock County

Cancer Site/Type Observed Expected SMR Unadjusted p-value
Paratoid/Salivary 9 10.79 0.83372
Esophagus 19 21.44 0.88596
Stomach 71 63.91 1.11081 0.17079
Colon 330 314.86 1.11081 0.18857
Rectosigmoid/Rectum 113 126.53 0.89305
Liver 10 11.31 0.88344
Sinus/Paranasal 6 3.89 1.53945 0.10027
Lung/Bronchus 365 471.00 0.77494
Bone 11 9.02 1.21913 0.19921
Breast 537 543.48 0.98807
Ovary 92 89.76 1.02489 0.38032
Bladder 204 172.77 1.18072 0.00921
Kidney/Renal Pelvis 87 76.99 1.12996 0.11699
Brain/CNS 55 66.33 0.82913
Thyroid 54 55.43 0.97411
Non-Hodgkin's Lymphoma 127 119.83 1.05979 0.23949
Multiple Myeloma 34 39.72 0.85598
Leukemia 100 75.00 1.33323 0.0024

Bingham County

Cancer Site/Type Observed Expected SMR Unadjusted p-value
Paratoid/Salivary 0 6.7
Esophagus 6 12.30 0.48764
Stomach 49 36.74 1.33347 0.02152
Colon 110 178.36 0.61670
Rectosigmoid/Rectum 65 72.87 0.89191
Liver 4 6.46 0.61891
Sinus/Paranasal 0 2.23
Lung/Bronchus 158 278.14 0.56805
Bone 9 5.07 1.77298 0.03467
Breast 254 301.59 0.84220
Ovary 46 49.86 0.92250
Bladder 57 101.64 0.56080
Kidney/Renal Pelvis 30 44.62 0.67229
Brain/CNS 46 37.58 1.22401 0.07655
Thyroid 25 30.17 0.82863
Non-Hodgkin's Lymphoma 66 68.82 0.95901
Multiple Myeloma 29 22.92 1.26513 0.08877
Leukemia 39 43.69 0.89262

Blaine County

Cancer Site/Type Observed Expected SMR Unadjusted p-value
Paratoid/Salivary 4 1.55 2.57417 0.02123
Esophagus 5 3.15 1.58725 0.09980
Stomach 6 8.89 0.67457
Colon 36 43.73 0.82316
Rectosigmoid/Rectum 21 17.98 1.16776 0.19973
Liver 3 1.67 1.80129 0.08809
Sinus/Paranasal 0 0.60
Lung/Bronchus 47 70.05 0.67093
Bone 0 1.53
Breast 107 84.61 1.26456 0.00810
Ovary 11 13.79 0.79737
Bladder 27 24.59 1.09783 0.27157
Kidney/Renal Pelvis 10 12.21 0.81912
Brain/CNS 4 11.07 0.36129
Thyroid 13 10.47 1.24212 0.17182
Non-Hodgkin's Lymphoma 27 18.23 1.48066 0.02004
Multiple Myeloma 02 5.82 0.34335
Leukemia 9 11.52 0.78094

Bonneville County

Cancer Site/Type Observed Expected SMR Unadjusted p-value
Paratoid/Salivary 4 10.53 0.37980
Esophagus 22 20.80 1.05729 0.34372
Stomach 60 61.27 0.97913
Colon 249 299.36 0.83177
Rectosigmoid/Rectum 125 121.66 1.02745 0.35893
Liver 12 11.09 1.08145 0.32188
Sinus/Paranasal 3 3.87 0.77396
Lung/Bronchus 245 459.71 0.53294
Bone 10 9.32 1.07195 0.33364
Breast 505 537.16 0.94012
Ovary 79 88.50 0.89265
Bladder 112 166.36 0.67324
Kidney/Renal Pelvis 70 76.23 0.91828
Brain/CNS 79 67.48 1.17061 0.07469
Thyroid 56 56.97 0.98283
Non-Hodgkin' s Lymphoma 107 118.64 0.90187
Multiple Myeloma 52 38.75 1.34191 0.01701
Leukemia 69 75.26 0.91676

Butte County

Cancer Site/Type Observed Expected SMR Unadjusted p-value
Paratoid/Salivary 0 0.65
Esophagus 1 1.28 0.78228
Stomach 6 4.02 1.49400 0.11236
Colon 11 19.42 0.56646
Rectosigmoid/Rectum 3 8.04 0.37301
Liver 0 0.68
Sinus/Paranasal 0 0.23
Lung/Bronchus 24 31.34 0.76565
Bone 0 0.45
Breast 30 30.58 0.98088
Ovary 3 5.01 0.59865
Bladder 8 11.41 0.70099
Kidney/Renal Pelvis 6 4.84 1.24018 0.21453
Brain/CNS 3 3.68 0.81562
Thyroid 2 2.79 0.71760
Non-Hodgkin' s Lymphoma 6 7.14 0.84078
Multiple Myeloma 2 2.47 0.80987
Leukemia 4 4.43 0.90388

Caribou County

Cancer Site/Type Observed Expected SMR Unadjusted p-value
Paratoid/Salivary 0 1.34
Esophagus 1 2.68 0.37269
Stomach 4 8.06 0.49578
Colon 21 39.10 0.53704
Rectosigmoid/Rectum 09 15.88 0.56673
Liver 2 1.42 1.40915 0.17118
Sinus/Paranasal 0 0.49
Lung/Bronchus 23 60.17 0.38222
Bone 0 1.10
Breast 52 65.61 0.79259
Ovary 1 10.84 0.09227
Bladder 11 22.01 0.49964
Kidney/Renal Pelvis 9 9.73 0.92501
Brain/CNS 4 8.21 0.48732
Thyroid 2 6.59 0.30347
Non-Hodgkin' s Lymphoma 12 15.14 0.79248
Multiple Myeloma 2 5.05 0.39572
Leukemia 10 9.49 1.05341 0.35380

Cassia County

Cancer Site/Type Observed Expected SMR Unadjusted p-value
Paratoid/Salivary 2 3.69 0.54159
Esophagus 5 7.34 0.68045
Stomach 21 22.63 0.92768
Colon 107 110.63 0.96718
Rectosigmoid/Rectum 50 44.80 1.11595 0.19541
Liver 5 3.88 1.28846 0.19650
Sinus/Paranasal 0 1.31
Lung/Bronchus 102 169.04 0.60339
Bone 1 2.77 0.36020
Breast 176 180.10 0.97723
Ovary 25 29.65 0.84300
Bladder 55 62.22 0.88385
Kidney/Renal Pelvis 16 26.58 0.60188
Brain/CNS 25 21.31 1.17314 0.18004
Thyroid 12 16.64 0.72101
Non-Hodgkin' s Lymphoma 33 40.78 0.80911
Multiple Myeloma 17 13.90 1.22267 0.16602
Leukemia 31 25.41 1.21984 0.11595

Clark County

Cancer Site/Type Observed Expected SMR Unadjusted p-value
Paratoid/Salivary 0 0.15
Esophagus 1 0.31 3.16696 0.04050
Stomach 2 0.97 2.04937 0.07592
Colon 5 4.50 1.10896 0.29856
Rectosigmoid/Rectum 2 1.90 1.04781 0.29864
Liver 0 0.16
Sinus/Paranasal 0 0.05
Lung/Bronchus 8 7.70 1.03846 0.36617
Bone 0 0.11
Breast 12 6.67 1.79655 0.01948
Ovary 0 1.09
Bladder 1 2.81 0.35501
Kidney/Renal Pelvis 0 1.19
Brain/CNS 2 0.91 2.17704 0.06597
Thyroid 0 0.68
Non-Hodgkin's Lymphoma 1 1.75 0.57089
Multiple Myeloma 0 0.59
Leukemia 2 1.08 1.85098 0.09569

Custer County

Cancer Site/Type Observed Expected SMR Unadjusted p-value
Paratoid/Salivary 1 0.84 1.18816 0.20625
Esophagus 2 1.67 1.19542 0.23568
Stomach 6 5.29 1.13363 0.28175
Colon 18 25.72 0.69983
Rectosigmoid/Rectum 6 10.68 0.56133
Liver 1 0.89 1.11874 0.22527
Sinus/Paranasal 0 0.30
Lung/Bronchus 26 42.01 0.61883
Bone 0 0.57
Breast 34 40.85 0.83221
Ovary 6 6.64 0.90362
Bladder 13 15.24 0.85255
Kidney/Renal Pelvis 4 6.49 0.61544
Brain/CNS 2 4.81 0.41521
Thyroid 5 3.77 1.32430 0.18085
Non-Hodgkin's Lymphoma 10 9.37 1.06615 0.33984
Multiple Myeloma 2 3.27 0.61051
Leukemia 4 5.75 0.69498

Fremont County

Cancer Site/Type Observed Expected SMR Unadjusted p-value
Paratoid/Salivary 4 1.98 2.01482 0.05134
Esophagus 2 3.97 0.50299
Stomach 7 12.10 0.57845
Colon 50 58.69 0.85190
Rectosigmoid/Rectum 34 24.00 1.41656 0.02059
Liver 3 2.09 1.43162 0.16051
Sinus/Paranasal 0 0.71
Lung/Bronchus 46 91.97 0.50015
Bone 1 1.51 0.65819
Breast 89 96.11 0.92593
Ovary 10 15.86 0.63037
Bladder 28 33.50 0.83577
Kidney/Renal Pelvis 5 14.44 0.34620
Brain/CNS 6 11.63 0.51578
Thyroid 9 8.93 1.00704 0.40431
Non-Hodgkin's Lymphoma 15 22.15 0.67690
Multiple Myeloma 4 7.52 0.53136
Leukemia 12 13.89 0.86374

Jefferson County

Cancer Site/Type Observed Expected SMR Unadjusted p-value
Paratoid/Salivary 5 2.63 1.90055 0.05134
Esophagus 2 5.31 0.37619
Stomach 13 15.93 0.81590
Colon 67 76.59 0.87474
Rectosigmoid/Rectum 28 31.32 0.89375
Liver 1 2.76 0.36145
Sinus/Paranasal 0 0.95
Lung/Bronchus 49 119.97 0.40844
Bone 2 2.13 0.93493
Breast 110 124.69 0.88216
Ovary 19 20.65 0.92006
Bladder 33 44.19 0.74673
Kidney/Renal Pelvis 8 19.14 0.41787
Brain/CNS 19 15.92 1.19324 0.18241
Thyroid 6 12.43 0.48255
Non-Hodgkin's Lymphoma 22 29.21 0.75308
Multiple Myeloma 8 9.73 0.82215
Leukemia 23 18.71 1.22897 0.13553

Jerome County

Cancer Site/Type Observed Expected SMR Unadjusted p-value
Paratoid/Salivary 2 3.10 0.64429
Esophagus 4 6.02 0.0.66370
Stomach 22 19.44 1.13139 0.23800
Colon 86 95.44 0.90101
Rectosigmoid/Rectum 34 38.66 0.87929
Liver 4 3.26 1.22713 0.23009
Sinus/Paranasal 0 1.08
Lung/Bronchus 127 146.34 0.86783
Bone 1 2.11 0.47386
Breast 129 152.46 0.84610
Ovary 22 24.90 0.88343
Bladder 48 54.01 0.88866
Kidney/Renal Pelvis 17 22.54 0.75400
Brain/CNS 16 17.08 0.93672
Thyroid 17 13.29 1.27826 0.12674
Non-Hodgkin's Lymphoma 28 33.74 0.82977
Multiple Myeloma 13 11.77 1.10382 0.29519
Leukemia 26 20.62 1.26093 0.10115

Lincoln County

Cancer Site/Type Observed Expected SMR Unadjusted p-value
Paratoid/Salivary 1 0.78 1.27986 0.18451
Esophagus 2 1.53 1.30684 0.19882
Stomach 3 5.02 0.59688
Colon 28 24.44 1.14540 0.20277
Rectosigmoid/Rectum 8 9.90 0.80787
Liver 0 0.82
Sinus/Paranasal 0 0.26
Lung/Bronchus 28 37.52 0.74611
Bone 0 0.50
Breast 27 37.04 0.72879
Ovary 4 6.04 0.66212
Bladder 7 14.00 0.49985
Kidney/Renal Pelvis 3 5.71 0.52479
Brain/CNS 7 4.18 1.67297 0.06286
Thyroid 2 3.11 0.64233
Non-Hodgkin's Lymphoma 7 8.38 0.83467
Multiple Myeloma 6 2.95 2.03271 0.03113
Leukemia 10 5.14 1.94481 0.01646

Madison County

Cancer Site/Type Observed Expected SMR Unadjusted p-value
Paratoid/Salivary 1 2.52 0.39578
Esophagus 3 5.27 0.56872
Stomach 19 13.60 1.39618 0.06162
Colon 56 64.06 0.87406
Rectosigmoid/Rectum 27 26.02 1.03757 0.37467
Liver 2 2.59 0.76989
Sinus/Paranasal 1 0.96 1.03676 0.25120
Lung/Bronchus 32 96.04 0.33319
Bone 2 2.72 0.73297
Breast 92 110.17 0.83506
Ovary 9 19.30 0.46610
Bladder 18 35.87 0.50176
Kidney/Renal Pelvis 8 16.69 0.47922
Brain/CNS 12 17.31 0.69321
Thyroid 13 13.38 0.97120
Non-Hodgkin's Lymphoma 32 28.80 1.11102 0.24024
Multiple Myeloma 11 8.76 1.25443 0.17516
Leukemia 12 19.05 0.62979

Minidoka County

Cancer Site/Type Observed Expected SMR Unadjusted p-value
Paratoid/Salivary 4 3.61 1.10522 0.29723
Esophagus 2 7.06 0.28308
Stomach 37 22.09 1.67452 0.00131
Colon 97 106.36 0.91197
Rectosigmoid/Rectum 48 43.82 1.09520 0.23620
Liver 6 3.82 1.56697 0.09363
Sinus/Paranasal 1 1.31 0.76116
Lung/Bronchus 132 170.14 0.77580
Bone 4 2.79 1.43087 0.15162
Breast 161 177.41 0.90748
Ovary 30 29.20 1.02719 0.39416
Bladder 56 61.43 0.91155
Kidney/Renal Pelvis 20 26.74 0.74792
Brain/CNS 28 21.47 1.30381 0.06982
Thyroid 13 16.89 0.76959
Non-Hodgkin's Lymphoma 29 40.65 0.71341
Multiple Myeloma 6 13.81 0.43419
Leukemia 16 25.26 0.63339

Power County

Cancer Site/Type Observed Expected SMR Unadjusted p-value
Paratoid/Salivary 0 1.15
Esophagus 3 2.26 1.32471 0.19350
Stomach 6 6.96 0.86186
Colon 31 33.74 0.91872
Rectosigmoid/Rectum 8 13.76 0.58117
Liver 0 1.21
Sinus/Paranasal 0 0.42
Lung/Bronchus 31 52.58 0.58961
Bone 1 0.93 1.07095 0.23989
Breast 56 56.84 0.98525
Ovary 5 9.36 0.53414
Bladder 12 19.20 0.62487
Kidney/Renal Pelvis 8 8.49 0.94237
Brain/CNS 7 7.03 0.99517
Thyroid 4 5.80 0.68948
Non-Hodgkin's Lymphoma 5 12.89 0.38795
Multiple Myeloma 7 4.32 1.62046 0.07249
Leukemia 4 8.09 0.49410

Twin Falls County

Cancer Site/Type Observed Expected SMR Unadjusted p-value
Paratoid/Salivary 15 11.82 1.26829 0.14333
Esophagus 21 22.96 0.91433
Stomach 58 75.10 0.77230
Colon 366 376.37 0.97245
Rectosigmoid/Rectum 153 148.94 1.02722 0.35015
Liver 12 12.39 0.96808
Sinus/Paranasal 2 3.98 0.50218
Lung/Bronchus 465 543.12 0.85615
Bone 8 7.54 1.06002 0.34450
Breast 541 593.41 0.91168
Ovary 80 96.66 0.82758
Bladder 186 203.92 0.91209
Kidney/Renal Pelvis 96 83.90 1.14422 0.08676
Brain/CNS 70 62.34 1.12284 0.15090
Thyroid 58 48.41 1.19804 0.07685
Non-Hodgkin's Lymphoma 127 124.97 1.01619 0.40522
Multiple Myeloma 38 44.10 0.86168
Leukemia 90 76.34 1.17896 0.05560

Note: Adjusting for the number of comparisons performed, no cancer sites/types were significantly elevated at p=.05.


Aggregate 17 County Study Area

Cancer Site/Type Observed Expected SMR Unadjusted p-value
Paratoid/Salivary 52 63.35 0.82078
Esophagus 101 125.43 0.80524
Stomach 390 382.10 1.02068 0.33116
Colon 1668 1871.44 0.89129
Rectosigmoid/Rectum 734 756.84 0.96982
Liver 65 66.57 0.97639
Sinus/Paranasal 13 22.70 0.57273
Lung/Bronchus 1908 2846.91 0.67020
Bone 50 50.26 0.99475
Breast 2912 3138.84 0.92773
Ovary 442 517.17 0.85465
Bladder 876 1045.24 0.83808
Kidney/Renal Pelvis 397 456.57 0.86953
Brain/CNS 385 378.39 1.01747 0.35458
Thyroid 291 305.81 0.95157
Non-Hodgkin's Lymphoma 654 700.55 0.93355
Multiple Myeloma 233 235.51 0.98933
Leukemia 461 438.77 1.05066 0.13924
Note: Adjusting for the number of comparisons performed, no cancer sites/types were significantly elevated at p=.05.

1983-1992 Idaho and 1987-1991 SEER Age-Adjusted Incidence Rates
Per 100,000 By Selected Primary Site

Site/Type SEER Idaho Site/Type SEER Idaho
Oral Cavity 10.5 9.9 Breast (female) 113.2 94.9
Esophagus 3.4 2.0 Ovary 15.6 13.9
Stomach 6.7 5.3 Bladder 18.2 15.9
Colon 34.0 28.1 Kidney 8.8 7.4
Rectum 13.8 11.1 Brain & CNS 6.7 6.3
Liver 2.4 1.6 Thyroid 4.5 4.4
Sinus -- 0.5 Lymphoma (non-Hodgkin' s) 15.0 12.2
Lung 57.9 44.7 Multiple Myeloma 4.1 4.1
Bone -- 0.8 Leukemia 10.2 9.8